N-Isovaleroylglycine

N-Isovaleroylglycine is a peptidylglycine α-amidating monooxygenase (PAM) inhibitor with a K_i value of 2.0 mM against human hsPAM. N-Isovaleroylglycine undergoes oxidative cleavage by purified rat PAM to produce fatty acid amide and glyoxylic acid. N-Isovaleroylglycine exerts competitive inhibition by binding to hsPAM, blocking the amidation of dansyl-Tyr-Val-Gly. N-Isovaleroylglycine exhibits lowered urinary abundance in MRSA-infected mice, which qualifies it as a non-invasive biomarker. N-Isovaleroylglycine can be used in studies related to Staphylococcus aureus pneumonia and diabetic foot^[1][2][3]. In Vitro:N-Isovaleroylglycine is amidated by purified recombinant type A rat medullary thyroid carcinoma PAM with a K_m of 2.0 mM, a V_max of 8.8 μmol/min/mg, and a relative V/K of 6.4^[2].
N-Isovaleroylglycine inhibits crude human serum PAM with a K_i of 2.0 mM, and acts as a substrate for purified rat PAM under matching conditions with a K_m of 3.8 mM^[2]. In Vivo:N-Isovaleroylglycine shows an 18% median decrease in urinary concentration in intranasal MRSA-induced pneumonia in male C57Bl/6 mice^[1].